Budsberg Steven C, Cross Alan R, Quandt Jane E, Pablo Luisito S, Runk Alice R
Department of Small Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens 30602, USA.
Am J Vet Res. 2002 Nov;63(11):1557-63. doi: 10.2460/ajvr.2002.63.1557.
To compare preoperative administration of meloxicam and butorphanol to perioperative administration of butorphanol alone for control of postoperative signs of pain in dogs.
40 client-owned dogs scheduled for surgical repair of a cranial cruciate ligament rupture.
Group-1 dogs received butorphanol (0.2 mg/kg, IV) and meloxicam (0.2 mg/kg, IV) just prior to surgery. Group-2 dogs received butorphanol just prior to surgery (0.2 mg/kg, IV) and at incision closure (0.1 mg/kg, IV). Pain assessment began 1 to 2 hours before surgery and from extubation until 24 hours after surgery by obtaining the following measurements: the visual analog scale (VAS) score, cumulative pain score (CPS), adjusted cumulative pain score, modified cumulative pain score, and the adjusted modified cumulative pain score (AMCPS). Serum cortisol concentration was measured between 12 to 24 and between 1 to 2 hours prior to surgery, and at 30 minutes, and 1, 2, 4, 8, 18, and 24 hours after extubation.
No significant differences between treatment groups were observed in CPS or VAS score. At 8, 9, 10, and 11 hours after extubation, meloxicam-butorphanol-treated dogs had a significantly lower AMCPS, compared with butorphanol-alone-treated dogs. Total serum cortisol concentration (area under the curve) during the measurement period was significantly lower in meloxicam-butorphanol-treated dogs, compared with butorphanol-alone treated dogs.
Preoperative single dose administration of meloxicam-butorphanol is equivalent to or slightly better than the administration of 2 perioperative doses of butorphanol for the control of postoperative signs of pain in dogs.
比较术前给予美洛昔康和布托啡诺与仅围手术期给予布托啡诺对控制犬术后疼痛体征的效果。
40只由客户拥有的犬，计划进行颅交叉韧带破裂的手术修复。
第1组犬在手术前接受布托啡诺（0.2毫克/千克，静脉注射）和美洛昔康（0.2毫克/千克，静脉注射）。第2组犬在手术前接受布托啡诺（0.2毫克/千克，静脉注射），并在切口缝合时接受（0.1毫克/千克，静脉注射）。疼痛评估在手术前1至2小时开始，从拔管后至术后24小时，通过获取以下测量值进行：视觉模拟评分（VAS）、累积疼痛评分（CPS）、调整后的累积疼痛评分、改良累积疼痛评分和调整后的改良累积疼痛评分（AMCPS）。在手术前12至24小时和1至2小时之间、拔管后30分钟以及1、2、4、8、18和24小时测量血清皮质醇浓度。
在CPS或VAS评分方面，各治疗组之间未观察到显著差异。在拔管后8、9、10和11小时，与仅接受布托啡诺治疗的犬相比，接受美洛昔康 - 布托啡诺治疗的犬的AMCPS显著更低。在测量期间，与仅接受布托啡诺治疗的犬相比，接受美洛昔康 - 布托啡诺治疗的犬的总血清皮质醇浓度（曲线下面积）显著更低。
术前单剂量给予美洛昔康 - 布托啡诺在控制犬术后疼痛体征方面等同于或略优于围手术期给予2剂布托啡诺。
